Rhenman & Partners Asset Management AB Purchases 45,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• Rhenman & Partners boosted its position in Structure Therapeutics (NASDAQ:GPCR) by 33.3%, purchasing 45,000 shares to hold 180,100 shares valued at about $5.04 million.
• Institutional ownership stands at 91.78%, with several funds increasing stakes (notably Readystate Asset Management's 237,188 shares worth ~$6.64M), indicating strong institutional interest.
• Analyst sentiment is generally bullish—a "Moderate Buy" consensus and average target of $107.90 with multiple price‑target upgrades—despite the company being loss‑making (consensus FY EPS ~ -$0.82) and a recent quarterly EPS miss.

Rhenman & Partners Asset Management AB grew its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 33.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 180,100 shares of the company's stock after buying an additional 45,000 shares during the quarter. Rhenman & Partners Asset Management AB owned 0.31% of Structure Therapeutics worth $5,043,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in GPCR. DNB Asset Management AS increased its stake in shares of Structure Therapeutics by 21.2% during the third quarter. DNB Asset Management AS now owns 12,888 shares of the company's stock valued at $361,000 after buying an additional 2,253 shares during the period. Private Capital Advisors Inc. purchased a new stake in Structure Therapeutics in the third quarter worth about $1,545,000. EverSource Wealth Advisors LLC lifted its stake in Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company's stock worth $30,000 after acquiring an additional 901 shares during the period. ANTIPODES PARTNERS Ltd grew its holdings in Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company's stock worth $114,000 after acquiring an additional 1,146 shares in the last quarter. Finally, Readystate Asset Management LP grew its holdings in Structure Therapeutics by 32.8% during the 3rd quarter. Readystate Asset Management LP now owns 237,188 shares of the company's stock worth $6,641,000 after acquiring an additional 58,576 shares in the last quarter. Institutional investors own 91.78% of the company's stock.

Trending Headlines about Structure Therapeutics

Here are the key news stories impacting Structure Therapeutics this week:

• Positive Sentiment: HC Wainwright retained a "Buy" rating and a $114 price target on GPCR, signaling continued analyst conviction in the company’s longer‑term clinical/strategic potential. Price Target Raised to $114.00
• Neutral Sentiment: Consensus current‑year EPS remains negative at about ($0.82) per share — consistent with a development‑stage biotech profile where revenue is limited and earnings are driven by R&D/SG&A spend. GPCR MarketBeat page
• Negative Sentiment: HC Wainwright sharply cut near‑term and multi‑year EPS forecasts across the board — Q1–Q4 2026 and FY2026–FY2030 were all revised lower (examples: FY2026 from about ($1.20) to ($1.72); FY2027 from ($1.70) to ($2.34)). Those downgrades imply higher expected cash burn or later commercialization/timeline risk and are likely the primary driver of today's negative price action. HC Wainwright estimates (MarketBeat)

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR opened at $57.73 on Friday. Structure Therapeutics Inc. Sponsored ADR has a fifty-two week low of $13.22 and a fifty-two week high of $94.90. The company has a market cap of $4.08 billion, a PE ratio of -73.08 and a beta of -1.80. The business has a 50-day simple moving average of $74.68 and a two-hundred day simple moving average of $48.20.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14). On average, sell-side analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on GPCR shares. The Goldman Sachs Group raised shares of Structure Therapeutics to a "strong-buy" rating in a research report on Tuesday, January 20th. JPMorgan Chase & Co. upped their target price on Structure Therapeutics from $65.00 to $105.00 and gave the stock an "overweight" rating in a report on Thursday, January 22nd. Guggenheim increased their target price on Structure Therapeutics from $90.00 to $140.00 and gave the company a "buy" rating in a research report on Tuesday, January 20th. Citizens Jmp reduced their price target on Structure Therapeutics from $120.00 to $113.00 and set a "market outperform" rating for the company in a research report on Friday, February 27th. Finally, HC Wainwright upped their price objective on Structure Therapeutics from $90.00 to $114.00 and gave the stock a "buy" rating in a research note on Monday, March 2nd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $107.90.

Structure Therapeutics Company Profile

Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.